Background: Hepatic cancer is a global major health threat with a relatively high mortality rate. Standard treatment of the disease includes resection and liver transplantation.

Objective: To determine clinical outcomes of stereotactic body radiation therapy in patients with liver tumor.

Materials and Methods: Patients with primary hepatic tumors or cholangiocarcinoma of stage T to TTTB in TNM staging and those with liver metastases were included in the study for analyses of
tumor response rate, local tumor control, disease-free survival, and overall survival after stereotactic body radiation therapy [SBRT].

Results: Among 25 tumor masses in 19 patients analyzed, the overall tumor response rate was 56% (complete response 32%; partial response 24%). The median administered biologically effective dose in Gy was 100 Gy. Local tumor control rates were 87.5% and 65.6% for two and three years, respectively. Disease-free survival was 41.2% and 15.4% for two and three years, respectively. The overall survival of the patients was 70.75% at one year. Tumors larger than 19.46 cc or 3.3 cm in diameter were associated with inferior tumor response rate.

Conclusion: These results suggest that SBRT might be an effective therapy in hepatic tumors given its high local tumor control rate. The major limitation of the treatment modality remains hepatic
function of the patients, which restricts doses to the tumor.

Keywords: Stereotactic body radiation therapy, Liver tumor, Hepatoma, Clinical outcomes